Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ir 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

orifarm healthcare a/s - ibuprofenas - gelis - 20 mg/ml; 50 mg/g; 200 mg; 400 mg - ibuprofen

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

a.c.r.a.f. s.p.a. - naprokseno natrio druska - plėvele dengtos tabletės - 220 mg - naproxen

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

reckitt benckiser (poland) s.a. - ibuprofenas - dengtos tabletės - 400 mg; 200 mg; 40 mg/ml - ibuprofen

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

fresenius kabi polska sp.z.o.o. - natrio chloridas/kalio chloridas/kalcio chloridas - infuzinis tirpalas - 8,6 g/0,3 g/0,33 g/1000 ml - electrolytes

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaceutical works polpharma s.a. - tinidazolas - plėvele dengtos tabletės - 500 mg - tinidazole

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

baxter holding b.v. - acikloviras - koncentratas infuziniam tirpalui - 25 mg/ml - aciclovir

Litwanja - Litwanjan - SMCA (Valstybinė vaistų kontrolės tarnyba)

stada arzneimittel ag - ibuprofenas/fenilefrino hidrochloridas - plėvele dengtos tabletės - 400 mg/10 mg - ibuprofen, combinations

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - citomegalovirusinės infekcijos - antivirusiniai vaistai sisteminiam naudojimui - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antivirusinių medžiagų.

Unjoni Ewropea - Litwanjan - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitas c, lėtinis - antivirusiniai vaistai sisteminiam naudojimui - victrelis yra skiriamas gydyti lėtiniu hepatitu c (lhc) 1 genotipo infekcija, kartu su peginterferonu alfa ir ribavirinu, suaugusiems pacientams su kompensuota kepenų liga, kuriems anksčiau negydytiems arba kuriems nepavyko po ankstesnio gydymo.